Tagrisso plus chemotherapy achieves nearly four-year median overall survival in EGFR-mutated advanced lung cancer, setting new global standard in phase III trial
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
The Ma’anshan site approval covers pastilles, oral liquids, and powders
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
The company has received approval from DCGI to begin patient enrolment and dosing in the country
These licenses are given in areas of infectious disease diagnostics, immunodiagnostics, and vaccine development
The partnership will create a first-of-its-kind, fully integrated offering for the development of mRNA drug products
Now integrates with Abbott’s instinct sensor and approved for type 2 diabetes
This is Lupin's first product using proprietary Nanomi's technology and has a 180-day CGT exclusivity
New targeted therapy offers hope for patients with unresectable or metastatic NSCLC harboring HER2 tyrosine kinase domain activating mutations
Subscribe To Our Newsletter & Stay Updated
